13Apr 2025
Inebilizumab Significantly Reduces Symptoms in Generalized Myasthenia Gravis

Inebilizumab Significantly Reduces Symptoms in Generalized Myasthenia Gravis

A Phase 3 trial found that inebilizumab, a CD19+ B-cell depleting antibody, significantly improved daily function and reduced disease severity in patients with generalized myasthenia gravis. Compared to placebo, it yielded greater MG-ADL and QMG score reductions by week 26, with no rise in serious adverse events, offering a promising new treatment option.

  • #family health

Like

Save

Share